Louisiana Tech University research series welcomes precision medicine, health-care expert

November 10, 2016

RUSTON, La. - Tim Cooley, former executive vice president of operations for molecular health and former director for health outcomes and economics at Eli Lilly, will visit Louisiana Tech University on November 14 to speak as part of the New Frontiers in Biomedical Research lecture series.

Cooley's will share his insights and expertise during a presentation titled, "Innovation in Healthcare and the Promise and Challenges of Precision Medicine" beginning at 3:30 p.m. in the auditorium of the Institute for Micromanufacturing on the Louisiana Tech campus. The event is free and open to the public.

"Mr. Cooley's visit will enlighten our students to innovation in the field of precision medicine and the role of the pharmaceutical industry in that area," said Dr. Jamie Newman, founder and co-organizer of the New Frontiers in Biomedical Research series. "This is a critical and growing area of research and development and something many of our students may find themselves a part of in the future."

Cooley is a senior technology leader with extensive experience managing information technology and operations for life science and healthcare organizations. He is recognized for driving business value through strategic vision, innovation and operational excellence.

"Today, we are arguably beginning to reap some of the benefits associated with the Human Genome Project and other basic science investments via the concept of precision medicine," explains Cooley. "However as we move forward, the promise of precision medicine and its cousin 'consumer driven medicine' are running into a range of challenges which threaten to limit rapid uptake of these advances. As we move forward, it is important to understand these challenges and encourage rapid adoption of new technology without sacrificing patient safety and quality."

This is the fourth year for the New Frontiers in Biomedical Research seminar program. As an interdisciplinary lecture series that focuses on advancements in the fields of biomedical engineering, biology, physics and chemistry, it strives to promote an understanding of human health and disease by interacting with leaders in these research fields. The series also seeks to expose students to growing areas of research and to enhance Louisiana Tech's own impacts in biomedical research.

The 2016-2017 series continues to expand on critical areas beyond the research bench to explore related career paths and the responsibility of research and education.

All New Frontiers in Biomedical Research seminars are free to attend and open to the public. Unless otherwise noted, seminars begin at 3:30 p.m. in University Hall on the Louisiana Tech campus, and are recorded for future viewing. For more information on the series, a schedule of speakers, and to view recordings of the seminars, visit the New Frontiers in Biomedical Research website at http://biomedicalresearch.wix.com/new-frontiers or contact Dr. Jamie Newman at jjnewman@latech.edu.
-end-


Louisiana Tech University

Related Biomedical Research Articles from Brightsurf:

General data protection regulation hinders global biomedical research
The European Union (EU) General Data Protection Regulation (GDPR) was designed to give EU citizens greater protection and control of their personal data, particularly when transferred to entities outside the EU.

Novel educational program puts a human face on biomedical research
The goal of translational research is to speed research breakthroughs into clinical practice.

Biomedical research may miss key information by ignoring genetic ancestry
A new study of Black residents of four distinct US cities reveals variations in genetic ancestry and social status that underscore the inadequacy of using skin color as a proxy for race in research.

Advances in cryo-EM materials may aid cancer and biomedical research
Cryogenic-Electron Microscopy (cryo-EM) has been a game changer in the field of medical research, but the substrate, used to freeze and view samples under a microscope, has not advanced much in decades.

World-first program uncovers errors in biomedical research results
Just like the wrong ingredients can spoil a cake, so too can the wrong ingredients spoil the results in biomedical research.

Scientists poised to study reproducibility of Brazilian biomedical research
A project to assess the reproducibility of biomedical research in Brazil has been described today in the open-access journal eLife.

Transparency and reproducibility of biomedical research is improving
New research publishing Nov. 20 in the open-access journal PLOS Biology from Joshua Wallach, Kevin Boyack, and John Ioannidis suggests that progress has been made in key areas of research transparency and reproducibility.

As private funding of biomedical research soars, new risks arise
Academic medical centers (AMCs) in the US are navigating an increasing shift in research funding from historic public funding (e.g., NIH) to private sources such as pharma and biotech companies, foundations, and charities, raising a host of new issues related to collaborative research models, intellectual property rights, and scientific and ethical oversight.

BGRF scientists co-publish research paper on blockchain & AI for biomedical applications
Biogerontology Research Foundation Chief Science Officer (CSO) co-authored the landmark paper in the journal Oncotarget on the convergence of blockchain and AI to decentralize and galvanize healthcare and biomedical research.

Promising new drug for Hep B tested at Texas Biomedical Research Institute
Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

Read More: Biomedical Research News and Biomedical Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.